INTERVENTION 1:	Intervention	0
Abemaciclib + Anastrozole	Intervention	1
anastrozole	CHEBI:2704	14-25
Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.	Intervention	2
anastrozole	CHEBI:2704	71-82
All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks.	Intervention	3
anastrozole	CHEBI:2704	73-84
Total treatment duration was 16 weeks.	Intervention	4
duration	PATO:0001309	16-24
INTERVENTION 2:	Intervention	5
Abemaciclib	Intervention	6
Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.	Intervention	7
All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole QD for an additional 14 weeks.	Intervention	8
anastrozole	CHEBI:2704	73-84
Total treatment duration was 16 weeks.	Intervention	9
duration	PATO:0001309	16-24
Inclusion Criteria:	Eligibility	0
Have postmenopausal status.	Eligibility	1
Adenocarcinoma of the breast.	Eligibility	2
adenocarcinoma	DOID:299	0-14
breast	UBERON:0000310	22-28
Breast tumor 1 centimeter (cm) in diameter, HR+, HER2-.	Eligibility	3
breast	UBERON:0000310	0-6
centimeter	UO:0000015	15-25
diameter	PATO:0001334	34-42
Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.	Eligibility	4
Primary breast cancer that is suitable for baseline core biopsy.	Eligibility	5
breast cancer	DOID:1612	8-21
Have adequate organ function.	Eligibility	6
organ	UBERON:0000062	14-19
function	BAO:0003117,BFO:0000034	20-28
Exclusion Criteria:	Eligibility	7
Bilateral invasive breast cancer.	Eligibility	8
bilateral	HP:0012832	0-9
breast cancer	DOID:1612	19-32
Metastatic breast cancer (local spread to axillary lymph nodes is permitted).	Eligibility	9
breast cancer	DOID:1612	11-24
lymph	UBERON:0002391	51-56
Inflammatory breast cancer.	Eligibility	10
breast cancer	DOID:1612	13-26
Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.	Eligibility	11
radiotherapy	OAE:0000235	26-38
breast cancer	DOID:1612	68-81
breast	UBERON:0000310	68-74
breast	UBERON:0000310	94-100
Prior radiotherapy to the ipsilateral chest wall for any malignancy.	Eligibility	12
radiotherapy	OAE:0000235	6-18
chest	UBERON:0001443	38-43
Prior anti-estrogen therapy.	Eligibility	13
anti-estrogen	CHEBI:50751	6-19
Outcome Measurement:	Results	0
Percent Change From Baseline to 2 Weeks in Ki67 Expression	Results	1
percent change	BAO:0001252	0-14
Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.	Results	2
tissue	UBERON:0000479	6-12
percent	UO:0000187	156-163
central	HP:0030645	204-211
Time frame: Baseline, 2 Weeks	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Abemaciclib + Anastrozole	Results	5
anastrozole	CHEBI:2704	31-42
Arm/Group Description: Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.	Results	6
anastrozole	CHEBI:2704	94-105
All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks.	Results	7
anastrozole	CHEBI:2704	73-84
Total treatment duration was 16 weeks.	Results	8
duration	PATO:0001309	16-24
Overall Number of Participants Analyzed: 59	Results	9
Geometric Mean (90% Confidence Interval)	Results	10
mean	BAO:0002173	10-14
Unit of Measure: Percent Change  -92.86        (-94.82 to -90.16)	Results	11
percent change	BAO:0001252	17-31
Results 2:	Results	12
Arm/Group Title: Abemaciclib	Results	13
Arm/Group Description: Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.	Results	14
All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole QD for an additional 14 weeks.	Results	15
anastrozole	CHEBI:2704	73-84
Total treatment duration was 16 weeks.	Results	16
duration	PATO:0001309	16-24
Overall Number of Participants Analyzed: 52	Results	17
Geometric Mean (90% Confidence Interval)	Results	18
mean	BAO:0002173	10-14
Unit of Measure: Percent Change  -90.52        (-93.12 to -86.93)	Results	19
percent change	BAO:0001252	17-31
Adverse Events 1:	Adverse Events	0
Total: 1/74 (1.35%)	Adverse Events	1
Neutropenia 0/74 (0.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
Acute coronary syndrome 0/74 (0.00%)	Adverse Events	3
acute coronary syndrome	HP:0033678	0-23
Angina pectoris 0/74 (0.00%)	Adverse Events	4
angina pectoris	HP:0001681	0-15
Myocardial infarction 0/74 (0.00%)	Adverse Events	5
myocardial infarction	HP:0001658,DOID:5844	0-21
Abdominal pain 1/74 (1.35%)	Adverse Events	6
abdominal pain	HP:0002027	0-14
Pancreatitis 0/74 (0.00%)	Adverse Events	7
pancreatitis	HP:0001733,DOID:4989	0-12
Mastitis 0/74 (0.00%)	Adverse Events	8
mastitis	DOID:10690	0-8
Fracture 0/74 (0.00%)	Adverse Events	9
Alanine aminotransferase increased 1/74 (1.35%)	Adverse Events	10
alanine	CHEBI:16449	0-7
Aspartate aminotransferase increased 1/74 (1.35%)	Adverse Events	11
aspartate	CHEBI:29995	0-9
Adverse Events 2:	Adverse Events	12
Total: 1/75 (1.33%)	Adverse Events	13
Neutropenia 0/75 (0.00%)	Adverse Events	14
neutropenia	HP:0001875,DOID:1227	0-11
Acute coronary syndrome 0/75 (0.00%)	Adverse Events	15
acute coronary syndrome	HP:0033678	0-23
Angina pectoris 0/75 (0.00%)	Adverse Events	16
angina pectoris	HP:0001681	0-15
Myocardial infarction 0/75 (0.00%)	Adverse Events	17
myocardial infarction	HP:0001658,DOID:5844	0-21
Abdominal pain 0/75 (0.00%)	Adverse Events	18
abdominal pain	HP:0002027	0-14
Pancreatitis 0/75 (0.00%)	Adverse Events	19
pancreatitis	HP:0001733,DOID:4989	0-12
Mastitis 0/75 (0.00%)	Adverse Events	20
mastitis	DOID:10690	0-8
Fracture 0/75 (0.00%)	Adverse Events	21
Alanine aminotransferase increased 0/75 (0.00%)	Adverse Events	22
alanine	CHEBI:16449	0-7
Aspartate aminotransferase increased 0/75 (0.00%)	Adverse Events	23
aspartate	CHEBI:29995	0-9
